6-methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3

  title={6-methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3},
  author={Shufeng Zhou and Philip Kestell and James W. Paxton},
  journal={European Journal of Drug Metabolism and Pharmacokinetics},
SummaryThe involvement of flavin-containing monooxygenase (FMO) in the 6-methylhydroxylation of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) was investigated by use of human liver microsomes and microsomes containing cDNA-expressed FMOs. The involvement of FMO in the formation of 6-methyl hydroxylate of DMXAA, 6-hydroxymethyl-5-methylxanthenone-4-acetic acid (6-OH-MXAA) in human liver microsomes was indicated by the fact that this biotransformation was… 
Flavin‐Containing Monooxygenase: The Role of Flavin‐Containing Monooxgenase in Lead Design and Selection
Compared with cytochrome P450, drugs and drug candidates that are metabolized by FMO possess less potential for toxicity and adverse drug–drug interactions, and the prospects for increasing druglike properties and decreasing adverse drug-drug interactions of a drug candidate are likely increased.
Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease
  • I. Phillips, E. Shephard
  • Biology, Chemistry
    Xenobiotica; the fate of foreign compounds in biological systems
  • 2019
Genetic variants of human flavin-containing monooxygenase 3 (FMO3) have been associated with a number of disorders, but additional studies are needed to confirm or refute such associations.
Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions
An overview of the metabolic reactions of drugs, natural products, physiological compounds, and other (general) chemicals catalyzed by flavin monooxygenase, monoamine oxidase, NAD(P)H quinone oxidoreductase, and molybdenum hydroxylase enzymes, including roles as substrates, inducers, and inhibitors of the enzymes.
Genetic variants of flavin-containing monooxygenases:consequences for drug metabolism
The metabolism of the anti-tubercular drug, thiacetazone (TAZ) by human FMOs in vitro and the disposition of TAZ in vivo in mice were studied, finding FMO2.1 to be significantly more efficient at TAZ oxygenation than EtaA, FMO1 and FMO3.
Predicting the Metabolic Sites by Flavin-Containing Monooxygenase on Drug Molecules Using SVM Classification on Computed Quantum Mechanics and Circular Fingerprints Molecular Descriptors
This work reveals that the SVM model built can accurately predict the potential SOMs for drug molecules that are metabolizable by the FMO enzymes.
Mass balance, excretion and metabolism of [14C] ASA404 in cancer patients in a phase I trial
This study defined the substantial excretion of ASA404, mainly as metabolites, in both urine and faeces (about one-third of the dose) after intravenous administration as well as two novel metabolites that were not reported by previous studies using nonradioactive techniques.
Drug-like Properties and ADME of Xanthone Derivatives: The Antechamber of Clinical Trials.
The last section of this review focuses on a case-study of the development of the drug candidate DMXAA, which has reached clinical trials, to provide the paths and the importance of PK/tox parameters of this scaffold.
Drug Metabolism: Other Phase I Enzymes
Drug metabolism by flavin-containing monooxygenases of human and mouse
Identification of roles for FMO1 and FMO5 in endogenous metabolism has implications for drug therapy and initiates an exciting area of research.


Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.
In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) isoenzyme involved in the 6-methylhydroxylation of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA) by using a human liver library and the involvement of CYP1A2 in DMXAA metabolism by human livers was demonstrated.
Flavin-containing monooxygenase-mediated N-oxidation of the M(1)-muscarinic agonist xanomeline.
The data and those in the literature suggest that the increased prevalence of N-oxidized metabolites of xanomeline after s.c. dosing as compared with oral dosing may be due to differences in the affinity of various FMO family members for xnomeline or to differencesIn exposure to xanmeline that these enzymes receive under different dosing regimens.
Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug.
The kinetics of DMXAA glucuronidation in vivo are likely to be linear and unaffected by the coadministration of most glucuronidated drugs, but plasmaDMXAA clearance may be decreased in patients with renal dysfunction, illustrating the utility of in vitro techniques for the prediction of potential drug interactions and other dispositional characteristics of newly developed anticancer drugs before their administration to patients.
Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver.
It is demonstrated that DXAA undergoes extensive acyl glucuronidation followed by biliary excretion in the isolated perfused rat liver, and its hepatic metabolism may be saturable, and DXAA seems to be more extensively metabolized than FAA.
The mammalian flavin-containing monooxygenases: molecular characterization and regulation of expression.
The flavin-containing monooxygenase (FMO) has been characterized in several mammalian species, including human, and may play an important role in the early steps of chemical toxicity.
Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids.
The 5,6- dimethyl and 5-methyl-6-methoxy are the most effective analogues, showing in vivo colon 38 activity comparable to that of FAA at 10-15-fold lower doses and superior activity to FAA at the respective optimal doses, and the former has been selected for detailed evaluation.
The present paper gives a detailed account of the investigations on rabbit liver microsomes and crude microsomal digests, which have led to postulate the hemoprotein nature of the pigment.
Measurement of protein using bicinchoninic acid.